Thorac Cardiovasc Surg
DOI: 10.1055/a-2461-3147
Reviews

HTK Solution Cardioplegia in Pediatric Patients: A Meta-analysis

1   Federal University of Minas Gerais Medicine School, Belo Horizonte, Brazil
,
Ana Clara Felix de Farias Santos
2   UNICID, Sao Paulo, Brazil
,
Nicole Pimenta dos Santos
3   UNIRIO, Rio de Janeiro, Brazil
,
Fernanda Valeriano Zamora
1   Federal University of Minas Gerais Medicine School, Belo Horizonte, Brazil
,
Belisa Brunow Ventura Biavatti
4   UNICAMP, Campinas, Sao Paulo, Brazil
,
João Pedro Costa Esteves Almuinha Salles
3   UNIRIO, Rio de Janeiro, Brazil
,
Horbert Soares Mendonca
5   Prevent Senior Private Health Operator, Sao Paulo, Brazil
› Author Affiliations
Preview

Abstract

Introduction Cardioplegia, a therapy designed to induce reversible cardiac arrest, revolutionized cardiovascular surgery. Among the various pharmacological approaches is the histidine-tryptophan-ketoglutarate (HTK) solution. Despite numerous studies, no meta-analysis has investigated the efficacy of the HTK solution in the pediatric population. Therefore, we aim to conduct a meta-analysis comparing HTK and other cardioplegia solutions in pediatric patients undergoing cardiovascular surgery.

Methods PubMed, Embase, and Cochrane databases were searched from inception through April 2024. Endpoints were computed in odds ratios (OR) with 95% confidence intervals (CI) for dichotomous variables, whereas continuous variables were compared using mean differences (MD) with 95% CI.

Results A total of 11 studies comprising 1,349 patients were included, of whom 677 (50.19%) received HTK cardioplegia. The results were similar between groups regarding mortality (OR 0.98; 95% CI 0.29, 3.29), length of hospital stay (MD 0.32 days; 95% CI −0.88, 1.51), Mechanical ventilation (MV) (MD −17.72 hours; 95% CI −51.29, 15.85), arrhythmias (OR 1.27; 95% CI 0.83, 1.95), and delayed sternal closure (OR 0.89; 95% 0.56, 1.43). However, transfusion volume was lower in the HTK group (MD −452.39; 95% CI −890.24, −14.53; p = 0.04).

Conclusion The use of HTK solution was demonstrated to be similar regarding its clinical efficacy to other approaches for cardioplegia, and it may present advantages to patients prone to hypervolemia.

Data Availability Statement

The data associated with the paper are available in PubMed, Cochrane, and Embase.


Authors' Contribution

All authors read and approved the final version of the manuscript.


Supplementary Material



Publication History

Received: 08 July 2024

Accepted: 31 October 2024

Accepted Manuscript online:
05 November 2024

Article published online:
29 November 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany